ES2196165T3 - Terapia de citoxina activada por radiacion. - Google Patents

Terapia de citoxina activada por radiacion.

Info

Publication number
ES2196165T3
ES2196165T3 ES96927219T ES96927219T ES2196165T3 ES 2196165 T3 ES2196165 T3 ES 2196165T3 ES 96927219 T ES96927219 T ES 96927219T ES 96927219 T ES96927219 T ES 96927219T ES 2196165 T3 ES2196165 T3 ES 2196165T3
Authority
ES
Spain
Prior art keywords
tumour cells
racp
prodrug
cytoxine
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96927219T
Other languages
English (en)
Inventor
William Alexander Denny
Moana Tercel
William Robert Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Application granted granted Critical
Publication of ES2196165T3 publication Critical patent/ES2196165T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/32—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by at least three rings
    • C07C225/34—Amino anthraquinones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

METODO DE TRATAMIENTO DE LA ENFERMEDAD NEOPLASICA QUE CONSTA DE LOS PASOS DE: A) ADMINISTRAR AL PACIENTE QUE REQUIERA DICHO TRATAMIENTO UNA CANTIDAD EFECTIVA DE UN PROFARMACO CON CITOTOXINA ACTIVADA CON RADICACION (PCAR) QUE TIENE UNA TOXICIDAD BAJA, QUE PUEDE REDUCIRSE CON AGENTES REDUCTORES GENERADOS MEDIANTE LA RADIOLISIS DE AGUA (EL ELECTRON EQUIPARADO Y/O EL RADICAL HIDROGENO) Y QUE, MEDIANTE REDUCCION, LIBERA UNA CANTIDAD SUFICIENTE DE UN EFECTOR CON POTENCIA CITOTOXICA SUFICIENTE PARA DESTRUIR LAS CELULAS TUMORALES; Y B) LA IRRADIACION DE DICHAS CELULAS TUMORALES PARA REDUCIR EL PROFARMACO QUE ESTA PRESENTE EN LA LOCALIZACION DE DICHAS CELULAS TUMORALES PARA LIBERAR DICHO EFECTOR CITOTOXICO. EN LAS REALIZACIONES PREFERENTES, EL PCAR TIENE LA FORMULA (I), (VI), (VII) O (VIII).
ES96927219T 1995-08-18 1996-08-19 Terapia de citoxina activada por radiacion. Expired - Lifetime ES2196165T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ27281595 1995-08-18

Publications (1)

Publication Number Publication Date
ES2196165T3 true ES2196165T3 (es) 2003-12-16

Family

ID=19925392

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96927219T Expired - Lifetime ES2196165T3 (es) 1995-08-18 1996-08-19 Terapia de citoxina activada por radiacion.

Country Status (9)

Country Link
US (1) US6071908A (es)
EP (2) EP0850224B1 (es)
JP (1) JP2000502988A (es)
AT (1) ATE236881T1 (es)
AU (1) AU722191B2 (es)
CA (1) CA2229460A1 (es)
DE (1) DE69627355T2 (es)
ES (1) ES2196165T3 (es)
WO (1) WO1997007101A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1465882B1 (en) 2001-12-21 2011-08-24 X-Ceptor Therapeutics, Inc. Hetrocyclic modulators of nuclear receptors
RU2011141121A (ru) 2009-03-11 2013-04-20 Окленд Юнисервисиз Лимитед Пролекарственные формы ингибиторов киназ и их применение в терапии
BR112012004720B1 (pt) * 2009-09-02 2021-06-29 Auckland Uniservices Limited Inibidores de cinase, seus usos, profármaco e composição farmacêutica que o compreende
US20140271453A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Methods for the early detection of lung cancer
CN113101372B (zh) * 2019-12-24 2025-02-14 北京大学 具有辐射响应基团的缀合物及其用途
CN120899945A (zh) * 2025-10-11 2025-11-07 浙江大学 一种基于有机-无机动态组装的肿瘤靶向诊疗一体化系统及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296030A (en) * 1980-04-09 1981-10-20 American Cyanamid Company Metal chelates of 1,4-bis(substituted-amino-5,8-dihydroxy-anthraquinones
NZ201084A (en) * 1982-06-25 1985-10-11 New Zealand Dev Finance 4-carboxamidoacridine derivatives and pharmaceutical compositions containing such

Also Published As

Publication number Publication date
EP1225169A1 (en) 2002-07-24
EP0850224B1 (en) 2003-04-09
ATE236881T1 (de) 2003-04-15
DE69627355D1 (de) 2003-05-15
AU722191B2 (en) 2000-07-27
US6071908A (en) 2000-06-06
AU6711196A (en) 1997-03-12
EP0850224A1 (en) 1998-07-01
WO1997007101A1 (en) 1997-02-27
DE69627355T2 (de) 2004-02-12
CA2229460A1 (en) 1997-02-27
JP2000502988A (ja) 2000-03-14

Similar Documents

Publication Publication Date Title
NZ292854A (en) Use of an photoactive compound to treat multiple sclerosis which is followed by light therapy
WO2002064163A3 (en) Reduction or prevention of pdt related inflammation
CA2168575A1 (en) Use of photodynamic therapy to treat prostatic tissue
MY124091A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
EP0802782A4 (en) PROPHYLACTIC AND THERAPEUTIC TREATMENT OF MAIN SENSITIZATION AND IRRITATION
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
DE69939705D1 (de) Behandlung der pompeschen krankheit
NZ333315A (en) Dipyridoxyl chelating agents and their metal chelates for treating free radicals induced conditions
RU94020410A (ru) Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых, пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
WO2001026704A3 (en) Targeted drug activation
ES2124307T3 (es) Derivados de 3-hidroxipiridin-4-ona como agentes de quelacion.
DK0841912T3 (da) 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning
ATE236881T1 (de) Durch strahlung aktivierte cytotoxin therapie
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
TR199802200A2 (xx) S�lfonamid s�bstit�e edilmi� benzopiran t�revleri, �retilme y�ntemi.
NZ511559A (en) Use of staurosporine derivatives for treating ocular neovascular diseases
IL121440A0 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
HUT70757A (en) Pharmaceutical compositions for treating skin disorders
IL102806A0 (en) Therapeutic agents
SU782810A1 (ru) Способ лечени кератитов
RU97111568A (ru) Способ лечения онкологических больных
Maruyama Work in progress: californium-252 brachytherapy plus fractionated irradiation for advanced tonsillar carcinoma.
RU94021014A (ru) Способ лечения злокачественных опухолей методом фотодинамической терапии
SU1747083A1 (ru) Способ лечени мужского бесплоди